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Background. The prevalence of coronary artery stenosis (CAS) at the initiation of renal replacement therapy (RRT) in chronic
kidney disease (CKD) patients has not been fully elucidated. Although coronary angiography is the gold standard in diagnosing
CAS its invasiveness and economic burden lead to searching for a noninvasive alternative method. In this study, we evaluated the
prevalence of CAS by multidetector row computed tomography (MDCT) and related risk factor to articulate the usefulness of
MDCT.Method. Seventy-four asymptomatic CKD patients who began dialysis were evaluated with echocardiography and MDCT.
The patients were stratified into two groups according to CAS and coronary artery calcification score (CACS) by MDCT to detect
silent CAS and evaluate its predictability for cardiac events. Results. CAS was seen in 24 (32.4%) of 74 asymptomatic CKD patients
on MDCT. Both groups showed increasing frequencies of CAS with age (𝑃 < 0.01), presence of diabetes (𝑃 < 0.05), uric acid
level (𝑃 < 0.01), and calcium score (𝑃 < 0.01). Multiple regression analysis revealed that age and uric acid level were independent
risk factors for CAS and high CACS in asymptomatic CKD patients at the initiation of dialysis. Patients with both CAS and high
CACS were presented with higher cardiac events rates compared to those without any of them. In Cox regression model, age and
the presence of CAS and high CACS onMDCTwere an independent risk factor for cardiac events in these patients. Conclusion. We
showed that CAS was highly seen in asymptomatic CKD patients starting dialysis. Moreover, both high CACS and CAS onMDCT
might predict cardiac events in these patients and MDCT can be a useful screening tool for evaluating coronary artery disease and
predicting cardiovascular mortality noninvasively.
1. Introduction
Cardiovascular disease is the most common cause of death in
patients with end-stage renal disease (ESRD) [1]. Coronary
artery calcification is observed in chronic kidney disease
(CKD) patients without undergoing dialysis and is pro-
gressed throughout dialysis [2, 3]. Consequently, stage 5
CKD patients at the initiation of renal replacement therapy
(RRT) may already be a high-risk group for coronary artery
disease (CAD) and the cardiac risk of these patients needs
to be assessed accordingly. Despite a couple of reports on
the high prevalence of coronary artery stenosis (CAS) in
such patients with coronary angiography [4, 5], it is not
generally accepted to perform invasive diagnostic procedure
routinely in asymptomatic patients. Evaluation of CAD in
CKD patients has been generally taken by noninvasive
imaging techniques such as stress echocardiography [6] and
single-photon emission computed tomography (SPECT) [7].
However, these examinations have certain limitations includ-
ing high false-positive rate, misinterpretation of a hidden
myocardial ischemia and/or infarction, and high preva-
lence of electrolyte disorders. Accordingly, more noninvasive
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and available tools are introduced to evaluate CAD in CKD
patients and new methods such as electron beam computed
tomography (EBCT) and multidetector computed tomogra-
phy (MDCT) are being raised as a modality for noninvasive
coronary imaging. However, EBCT is not widely used due
to its costs and MDCT is more widely accepted due to its
high accuracy. The purpose of this study is to evaluate the
prevalence of CAS by MDCT and the usefulness of MDCT
in predicting cardiac disease in asymptomatic stage 5 CKD
patients at initiation of RRT.
2. Materials and Methods
2.1. Subjects and Study Design. We enrolled 74 consecutive
patients (46male, 28 female;mean age 56.5± 13.8 years; range
24–80 years)who startedRRT in the dialysis unit of Severance
Hospital, College of Medicine. Exclusion criteria included a
history of angina or acute myocardial infarction, a history
of malignancy, previous allergic reactions to iodine contrast
media, previous percutaneous transluminal coronary stent
placement, and previous bypass surgery. The study protocol
was approved by the Institutional Review Board of Yonsei
University Hospital, and all patients gave written informed
consent.
Medical charts were reviewed for clinical history and
medications. MDCT and echocardiography were performed
on all patients within 7 days after the initiation of RRT,
and coronary angiography was recommended for those who
showed luminal diameter narrowing of >50% of any major
coronary arteries. Fasting blood samples were analyzed for
total cholesterol, high-density lipoprotein (HDL) choles-
terol, low-density lipoprotein (LDL) cholesterol, triglyc-
erides, plasma homocysteine, plasma fibrinogen, free fatty
acid, high sensitivity C-reactive protein (hsCRP), and
lipoprotein (a).
Cardiac eventswere defined as nonfatal angina pectoris or
myocardial infarction, heart failure requiring hospitalization,
and cardiac death. Unstable angina and acute myocardial
infarction were diagnosed by the presence of typical angina
symptoms, ischemic change or QRS change on ECG, and
elevated serum cardiac enzyme levels. Heart failure was
diagnosed with typical symptoms such as dyspnea, shortness
of breath, or raised jugular venous pressure with systolic
or diastolic dysfunction by echocardiography which is in
accordance with guideline from European Society of Cardi-
ology [8]. Cerebrovascular disease (transient ischemic attack,
cerebral infarction, or cerebral hemorrhage) was confirmed
both by typical symptoms with physical findings and by
computed tomography (CT) or magnetic resonance imaging
(MRI). Peripheral vascular disease was diagnosed when the
patient had typical symptoms, abnormal ankle brachial pres-
sure index (ABPI), positive CT or CT angiography findings,
or peripheral artery stenosis confirmed by catheterization.
Cardiac death was defined as death with documentation of a
significant arrhythmia, cardiac arrest, or death attributable to
congestive heart failure or myocardial infarction and sudden
death. Elective follow-up revascularization procedures were
not considered to be cardiac events.
2.2. MDCT Protocol. All computed tomography angiogra-
phies (CTAs) were taken by 64-MDCT (Somatom Sensation
64, Siemens, Germany). Heart rate of each patient was
checked before CT scan and in patients with more than
65 beat per minute (bpm), 100mg of Metoprolol (Selokeen,
AstraZeneca Pharmaceutics, UK) was administered. After 1-
hour administration of Metoprolol, heart rate was rechecked.
Images for coronary calcium score were taken before contrast
media injection, and scan range was from tracheobronchial
bifurcation to diaphragm. Parameters of coronary calcium
scan were 120Kvp, 33mAs, slice thickness 0.6mm, and feed
18mm.The protocol of CTA had scan parameters as follows:
120Kvp, 500mA, pitch 0.2, slice thickness 0.75mm, colli-
mation 0.6mm, and gantry rotation time 0.33 sec. All CTAs
were taken with a single-breath hold (10–13 s), 20G needle
through right antecubital or right wrist venous route, two
kinds of nonionic water-soluble tri-iodinated contrast media
(Ultravist 300mg I/mL, Shering, Germany, and Omnipaque
300mg I/mL, Amersham Health, Norway), and test bolus
method. At first, test bolus images were taken using contrast
media 10 cc with 4 cc/sec injection flow rate. Housefield unit
(HU) of ascending aorta was analyzed by time-density calcu-
lation program (DynEva, Siemens, Germany).The amount of
contrast media and normal saline was calculated according
to cardiac scan time of each CTA with injection flow rate
4 cc/sec (contrast media) and 5 cc/sec (normal saline).
Every coronary artery was analyzed by two methods,
segment and diameter. Segmental analysis was according to
the 15-segment American Heart Association model of the
coronary tree. In addition to the segmental analysis, if the
artery showed diameter less than 1.5mm, it was grouped as
difficult to assessment.
Coronary calcium score and coronary stenosis were
analyzed in all CTA. Calcium score was estimated using
CAC-analysis software (Cascore, Siemens, Germany) by the
Agatston score system [9] with minimal level of 130HU and
every lesion was sorted out according to its score as up to 100,
101 to 400, 401 to 999, and 1000 or more.
Degree of coronary stenosis was divided as insignificant
or significant stenosis. Criterion for significant luminal nar-
rowing was defined as over 50% of luminal narrowing by
diameter compared to those of normal portions of stenotic
coronary arteries, and criteria of normal portions were
proximal or distal part of stenotic lesions. All radiologic
studies were interpreted independently by 2 experienced
radiologists without knowledge of alternate result or clinical
parameter.
2.3. Statistical Analysis. All values are expressed as the
means ± standard deviation (SD). To compare differences
between the significant coronary stenosis group and non-
significant stenosis group, independent t-test was applied.
Multiple linear regression analysis was used to evaluate
independent predictors of coronary artery stenosis (CAS)
and coronary artery calcification score (CACS). To evaluate
independent predictors for adverse cardiac outcomes, mul-
tivariate Cox proportional hazard model was used. Hazard
ratios (HR) are presented with 95% confidence intervals in
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parentheses. Values of 𝑃 < 0.05 were considered to indicate
statistical significance. Statistical analysis was performed
using SPSS for Windows Ver. 19.0 (SPSS, Inc., Chicago, IL,
USA).
3. Results
3.1. Baseline Characteristics and Biochemical Data. The base-
line characteristics of patients in present study are sum-
marized in Table 1. Sixty-two percent of the study subjects
were males. Their ages ranged from 24 to 80 years (mean
age 56.5 ± 13.8 years). Thirty-eight (51.4%) patients had
diabetes. Thirty-eight patients (51.4%) were started on HD,
and 36 patients (48.6%) received CAPD. Twenty patients
(27.0%) were smokers. Sixty-two (83.8%) patients received
angiotensin-converting enzyme inhibitors or angiotensin-
II receptor blockers. Thirty-three (44.6%) patients received
statin treatment and 25 (33.8%) patients took calcium-based
phosphate-binding agents. The mean CACS was 144.1 ±
286.5mm3, ranging from 0 to 1644mm3. Twenty-nine
patients of 74 patients (39.1%) had no calcium deposition in
their coronary arteries.
Patients were stratified into two groups according to
CACS andCAS, noCACS andnoCAS (CACS< 21.4 andCAS
< 50%) versusCACSorCAS (≥21.4 orCAS≥ 50%).The group
with CACS or CAS showed statistically higher age (𝑃 < 0.01),
the prevalence of diabetes (𝑃 < 0.05), and serum uric acid
level (𝑃 < 0.01). No significant differences were observed
in any other variables across the two groups (Table 2). A
total of 24 of the 74 patients (32.4%) showed coronary artery
stenosis. Seventeen of the 24 patients (70.8%) with CAS had
diabetes. In the group with diabetes, the prevalence of CAS
was 44.7%, while that in the group without diabetes was
19.4%. The prevalence of CAS in patients with diabetes was
significantly higher than that in patients without diabetes
(𝑃 < 0.05). Thirteen out of the 24 patients (54.1%) with
severe stenosis of coronary artery (>50%) agreed to undergo
coronary angiography. Eleven out of thirteen patients were
the patients with diabetes and two patients were the patients
without diabetes. Of these 13 patients, 6 (46.2%) had single-
vessel disease, two (15.4%) had two-vessel disease, and five
(38.4%) had triple-vessel disease on MDCT (Table 3).
3.2. Independent Predictors of Coronary Artery Stenosis and
Coronary Artery Calcium Score in Asymptomatic Patients
Starting Dialysis. In univariate analysis, age (hazard ratio
(HR) 1.092; 95% confidence interval CI 1.043–1.144; 𝑃 <
0.01), the presence of diabetes (HR 0.330; 95% CI 0.128–
0.854; 𝑃 < 0.05), CACS (HR 1.281; 95% CI 1.085–1.514;
𝑃 < 0.01), uric acid levels (HR 2.090; 95% CI 1.359–3.215;
𝑃 < 0.01), and LDL (𝛽 = 0.259, 𝑃 < 0.05) were associated
with CACS and CAS. Among these variables, age (𝛽 = 0.483,
𝑃 < 0.01) and uric acid levels (𝛽 = 0.357, 𝑃 < 0.01)
were independently associated with CACS and CAS in a
multivariate linear regression model (Table 4).
3.3. Prediction of Cardiac Events. In the univariate Cox analy-
sis, age, the presence of diabetes, serumuric acid levels, serum
Table 1: Baseline characteristics and biochemical data.
All patients (𝑛 = 74)
Age (years) 56.5 ± 13.8 (24–80)
Sex (male : female) 46 : 28
Diabetes mellitus, 𝑛 (%) 38 (51.4)
SBP (mmHg) 140.6 ± 19.5 (100–195)
DBP (mmHg) 78.1 ± 12.0 (50–120)
Hb (g/dL) 8.6 ± 1.5 (4.0–13.1)
Calcium (mg/dL) 8.3 ± 1.1 (5.5–12.3)
Phosphate (mg/dL) 5.3 ± 1.5 (1.8–11.2)
iPTH (pg/mL) 163.2 ± 124.4 (5.7–534.9)
hsCRP (mg/L) 10.1 ± 19.0 (0.15–130.0)
Albumin (g/dL) 3.4 ± 0.6 (2.2–4.6)
Total cholesterol (mg/dL) 174.3 ± 48.6 (77–439)
HDL-C (mg/dL) 39.2 ± 10.7 (20.0–71.0)
LDL-C (mg/dL) 109.6 ± 43.7 (35.8–314.8)
Triglyceride (mg/dL) 130.2 ± 55.7 (39–351)
Free fatty acid (uEq/L) 297.2 ± 199.3 (22–971)
Lipoprotein(a) (mg/dL) 51.4 ± 50.6 (0.7–299)
Fibrinogen (mg/dL) 474.3 ± 133.8 (264–958)
PAI-1 16.7 ± 10.0 (6.7–51.3)
Homocysteine (umol/L) 20.5 ± 14.5 (5.4–124.4)
EF (%) 61.3 ± 10.0 (28–78)
LVMI 35.5 ± 13.5 (13.7–78.1)
CACS 144.1 ± 286.5 (0–1644)
Cause of ESRD, 𝑛 (%)
DM nephropathy 41 (55.4%)
Hypertensive nephropathy 19 (25.6%)
Chronic Glomerulonephritis 8 (10.8%)
Etc 4
unknown 2
All values are expressed as mean ± SD; SBP: systolic blood pressure; DBP:
diastolic blood pressure; Hb: hemoglobin; iPTH: intact parathyroid intact
hormone; hsCRP: high sensitivity C-reactive protein; HDL: high density
lipoprotein; LDL: low density lipoprotein; PAI-1: plasminogen activator
inhibitor-1; EF: ejection fraction; LVMI: left ventricular mass index; CACS:
coronary artery calcium score.
LDL level, and the presence of CAS and CACS predicted
cardiac events. Age (HR 1.064; 95% CI 1.018–1.112; 𝑃 < 0.01)
and the presence of CAS and CACS (HR 0.216; 95% CI 0.051–
0.916) were independent risk factors in the multivariate Cox
analysis (Table 5).
4. Discussion
Due to several limitation of coronary angiography (CAG),
there has been a constant effort to replace coronary angiog-
raphy with noninvasive apparatus. Single-photon emission
computed tomography (SPECT) is a noninvasive pharmaco-
logic stress test which is useful in debilitated patients, such
as dialysis patients [10]. However, SPECT overlooks patients
with single vessel disease, balanced multivessel disease with
global ischemia, and collaterals that prevent detection of
different flow [11]. Electron beam computed tomography
(EBCT) was considered as a potential screening method
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Table 2: Basic characteristics of the two groups according to CACS
and CAS by MDCT.
No CACS/CAS
(𝑛 = 33)
CACS or CAS
(𝑛 = 41)
𝑃 value
Age (years) 49.0 ± 14.2 62.5 ± 10.2 <0.01
Sex
(male : female) 20 : 13 26 : 15
NS
Diabetes
mellitus, 𝑛 (%) 12 (36.3%) 26 (63.4%)
<0.05
SBP (mmHg) 140.3 ± 21.9 140.8 ± 17.6 NS
DBP (mmHg) 79.7 ± 12.8 76.6 ± 11.4 NS
Hb (g/dL) 8.5 ± 1.8 8.8 ± 1.3 NS
Calcium
(mg/dL) 8.2 ± 1.1 8.3 ± 1.2
NS
Phosphate
(mg/dL) 5.6 ± 1.8 5.0 ± 1.2
NS
iPTH (pg/mL) 184.0 ± 137.9 145.9 ± 110.9 NS
Uric acid 6.2 ± 1.4 7.5 ± 1.2 <0.01
hsCRP (mg/L) 10.5 ± 25.0 9.6 ± 13.4 NS
Albumin (g/dL) 3.4 ± 0.7 3.4 ± 0.5 NS
TC (mg/dL) 167.5 ± 34.9 179.7 ± 57.0 NS
HDL-C
(mg/dL) 42.0 ± 12.3 37.2 ± 8.9
NS
LDL-C (mg/dL) 99.0 ± 31.6 117.4 ± 49.6 NS
Triglyceride
(mg/dL) 124.3 ± 48.7 134.8 ± 60.9
NS
Free fatty acid
(uEq/L) 299.3 ± 234.5 295.5 ± 169.9
NS
Lipoprotein(a)
(mg/dL) 55.4 ± 47.3 48.3 ± 53.3
NS
Fibrinogen
(mg/dL) 481.7 ± 130.5 468.4 ± 138.0
NS
PAI-1 15.8 ± 7.6 17.2 ± 11.4 NS
Homocysteine
(umol/L) 22.1 ± 20.9 19.2 ± 6.6
NS
EF (%) 61.3 ± 12.7 61.4 ± 7.8 NS
LVMI 33.1 ± 9.0 36.9 ± 15.7 NS
All values are expressed as mean ± SD; SBP: systolic blood pressure; DBP:
diastolic blood pressure; Hb: hemoglobin; iPTH: intact parathyroid intact
hormone; hsCRP: high sensitivity C-reactive protein; HDL: high density
lipoprotein; LDL: low density lipoprotein; PAI-1: plasminogen activator
inhibitor-1; EF: ejection fraction; LVMI: left ventricular mass index; CACS:
coronary artery calcium score; NS: not significant.
by several groups [12, 13]. But, due to its slow scanning
rate, EBCT has led to frequent artifact and low resolution,
which led to inaccurate assessment of CAS [14]. Recently, 64-
channel MDCT has emerged as a strong potential screening
method. MDCT is superior to other apparatus, because
MDCT shows reduced cardiac motion artifact and higher
resolution and needs less amount of dye infusion which is
crucial in CKD patients.
Table 3: Prevalence of CAS by MDCT among 74 asymptomatic
CKD patients.
DM
(𝑛 = 38)
Non-DM
(𝑛 = 36)
PCI
(𝑛 = 13)
CAS positive, 𝑛 (%) 24 (32.1) 17 7 13
One vessel, 𝑛 (%) 15 (62.5) 9 6 6
Two vessels, 𝑛 (%) 3 (12.5) 1 2 2
Three vessels, 𝑛 (%) 6 (25.0) 5 1 5
Table 4: Multiple linear regressions of factors associated with CAS
and CACS in CKD patients at the start of dialysis.
Variables Univariate analysis Multivariate analysis
𝛽 𝑃 value 𝛽 𝑃 value
Age 0.488 <0.01 0.401 <0.01
diabetes 0.269 <0.05 0.153 NS
CACS 0.452 <0.01 0.152 NS
Uric acid 0.436 <0.01 3.071 <0.05
LDL 0.209 NS — —
EF 0.007 NS — —
SBP 0.012 NS — —
hsCRP 0.025 NS — —
CACS: coronary artery calcium score; LDL: low density lipoprotein; EF:
ejection fraction; SBP: systolic blood pressure; hsCRP: high sensitivity
C-reactive protein; NS: not significant.
Table 5: Cox regression models in CKD patients at the start of
dialysis.
HR (95% CI) 𝑃 value
Age 1.064 (1.018∼1.112) <0.01
The presence
of diabetes 0.469 (0.184∼1.196) NS
SBP 1.009 (0.981∼1.038) NS
Uric acid 0.726 (0.515∼1.023) NS
LDL 0.987 (0.972∼1.001) NS
CACS + CAS 0.216 (0.051∼0.916) <0.05
SBP: systolic blood pressure; LDL: low density lipoprotein; CACS: coronary
artery calcium score; CAS: coronary artery stenosis; NS: not significant.
In this study, we have demonstrated that (1) coronary
artery stenosis (CAS) is highly prevalent in asymptomatic
CKD patients at the start of renal replacement therapy, (2)
age and serum uric acid level are independent risk factors for
CAS and CACS inMDCT, and (3) CACS and CAS onMDCT
are useful in predicting cardiac events in these patients.
Generally, the prevalence of significant CAS (10%) among
dialysis patients was believed not to be different from that in
the general population (5∼10%) [8, 15]. However, many other
recent reports have contradicted this theory and have shown
a high prevalence of CAS in patients who were receiving
dialysis treatment [16]. Additionally, there have been a few
reports about the prevalence of CAS at the initiation of
dialysis therapy [4, 5, 16]. Ohtake et al. reported that 53.3%
patients of asymptomatic CKD patients who underwent
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coronary angiography showed significant CAS [5]. In this
study, the prevalence of CAS was as high as 32% but relatively
low compared to a previous study by Ohtake et al. The
discrepancy might be due to several reasons. Selection bias
from a small sample size and a difference in ethnicity may
have been attributed to such a difference. And MDCT is
a less sensitive method compared to coronary angiography.
However the strict exclusion criteria should have excluded
possible subclinical ischemic heart disease.
Interestingly, CAS was not affected by serum Ca, P,
and PTH levels which have been believed to have grave
influences on calcification pathophysiology in ESRDpatients.
Thus, we can assume that unknown underlying risks other
than Ca or P levels seem to be responsible, and certain
inflammatory process may be involved. Further research is
needed regarding this aspect. Our study also shows that
conventional risk factors for atherosclerosis such as hyper-
tension or hyperlipidemia did not differ between the two
groups. As seen in several recent studies, our study shows that
coronary artery calcification in ESRD patients can be affected
by uric acid level. Elevated serum uric acid level can result in
coronary calcification and eventually coronary artery stenosis
through inflammatory activation, metabolic disorders, and
calcium deposition [17–21].
The patients with both CACS and CASwere at higher risk
for cardiovascular complication compared to those without
any of them.Thus, MDCT, which can assess both parameters
simultaneous, is a very useful, noninvasive tool in predicting
cardiac disease in CKD patients.
However, this study has several limitations. First, this
study is a single-center study with a small number of patients.
Larger multicenter studies will be essential in examining
MDCT for the diagnosis of coronary artery stenosis. Sec-
ond, no head-to-head comparison was done with functional
tests such as SPECT. Third, coronary angiography was not
performed on patients whose MDCT results were negative
because it was considered unethical. Therefore false-negative
MDCT results were not evaluated.
In conclusion, nearly 30% of asymptomatic ESRD
patients who start RRT have significant CAS.Thus,MDCT of
the coronary arteries can be a useful screening method in
predicting cardiovascular events in ESRD patients.
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